Is Compounded Semaglutide FDA Approved? Legal Status and Risks in 2026
No. Compounded semaglutide is not FDA approved and never has been. The shortage-based pathway that let pharmacies compound it closed in 2025, courts upheld the FDA in August 2026, and only narrow patient-specific exceptions remain.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
No. Compounded semaglutide is not FDA approved, and no compounded drug ever goes through FDA approval. The agency does not review compounded drugs for safety, effectiveness, or quality before they are marketed [1][4]. The only FDA-approved semaglutide products are Wegovy injection, Ozempic injection, and Rybelsus tablets [9]. Compounded drugs are also not generics — generic drugs are FDA-approved before marketing, while compounded drugs are not [4][12].
As for legality in 2026: the special pathway that allowed pharmacies to compound semaglutide copies during the national shortage closed in 2025. The FDA declared the semaglutide injection shortage resolved on February 21, 2025, and its enforcement discretion ended on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities [2]. Federal courts, including the Fifth Circuit on August 27, 2026, upheld the FDA’s decision [13][14]. A narrow exception still exists for an identified patient with a documented, clinically significant need, and the FDA has stated it does not intend to act against a compounder filling four or fewer prescriptions of a copy per calendar month [2].
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy is a state-licensed pharmacy that compounds a drug for an individual patient based on a prescription it has received [2]. A 503B outsourcing facility compounds on a larger scale, and its use of bulk drug substances (active ingredients) is restricted: it generally cannot compound from a bulk substance unless that substance appears on the 503B bulks list, or the drug compounded from it is on the FDA’s drug shortage list at the time of compounding, distribution, and dispensing [2][6].
Both tracks carry copy restrictions with a statutory basis in 21 U.S.C. 353a(b)(1)(D) and 353b(a)(5): a compounder may not regularly or inordinately compound drugs that are essentially copies of commercially available drugs [13]. One quality-related difference the FDA has flagged in import alert documents: compounders whose drugs meet the conditions of section 503A are exempt from CGMP requirements, including the requirement to ensure the API used in manufacturing meets specifications for impurities or potency [8].
| Feature | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Who it serves | An individual patient, on receipt of a prescription [2] | Larger-scale compounding [2] |
| Bulk substance use | Copy restrictions apply [2][13] | Only if on the 503B bulks list or the drug is on the shortage list [2][6] |
| Copy of a commercial drug | Not regularly or in inordinate amounts [2] | Restricted under 21 U.S.C. 353b(a)(5) [13] |
Why was compounded semaglutide allowed in the first place?
Federal law restricts compounding drugs that are essentially copies of commercially available or approved products, but those restrictions are relaxed in important respects while a drug appears on the FDA’s drug shortage list [13][14]. The FDA added Wegovy to the shortage list on March 31, 2022, and Ozempic on August 23, 2022 [13]. While the drugs were listed, pharmacies and outsourcing facilities that met the statutory conditions could compound semaglutide to satisfy demand [13].
GLP-1 drugs were never on the 503A or 503B bulks lists — their compounding was permitted only through the shortage pathway, and that pathway has closed as the FDA resolved the tirzepatide and semaglutide shortages [10].
When did the FDA’s enforcement discretion end?
On February 21, 2025, the FDA determined the shortage of semaglutide injection products was resolved, after confirming with the manufacturer that availability and manufacturing capacity could meet present and projected national demand [2]. To avoid disrupting patient treatment, the agency gave compounders transition windows [2]:
- 503A pharmacies and physicians: until April 22, 2025 (60 calendar days) [2]
- 503B outsourcing facilities: until May 22, 2025 (90 calendar days) [2]
For tirzepatide, the FDA declared the shortage resolved on December 19, 2024, with discretion ending February 18, 2025 for 503A compounders and March 19, 2025 for 503B facilities [2][11]. The FDA noted it may still act on other violations, such as findings that a product is of substandard quality or otherwise unsafe [2].
Did the courts side with the compounders or the FDA?
The courts sided with the FDA at every stage. The Outsourcing Facilities Association and FarmaKeio Superior Custom Compounding sued, and Novo Nordisk intervened as a defendant [13]. On April 24, 2025, the Northern District of Texas denied the compounders’ preliminary injunction motion in the semaglutide case, 4:25-cv-00174 [2][13]. The same court upheld the FDA in the tirzepatide case on May 7, 2025, and entered summary judgment for the FDA in the semaglutide case on June 13, 2025 [11][13].
On August 27, 2026, the Fifth Circuit affirmed both judgments — No. 25-10758 (semaglutide) and No. 25-10600 (tirzepatide) — in unpublished decisions [13][14]. The court held that any error by the FDA in not using notice-and-comment procedures was harmless, that the delisting action was not arbitrary or capricious, and that the FDA reasonably relied on manufacturer supply and inventory data over contrary evidence such as website screenshots and patient reports [13][14].
What can a pharmacy still legally compound in 2026?
Under the FDA’s April 1, 2026 policy statement, a compounded drug is essentially a copy of a commercially available drug if it has the same active pharmaceutical ingredient in the same, similar, or easily substitutable strength, and the commercial product can be used by the same route of administration [2]. The exception: a prescriber determines and documents that the compounded product contains a change producing a significant difference for an identified individual patient [2][14].
Adding vitamin B12 (cyanocobalamin) to semaglutide does not escape the copy test by itself. The FDA states it may consider a semaglutide-plus-B12 product essentially a copy when it is given by the same route (such as injection) and the amounts of semaglutide and B12 are within 10% of the strengths of the respective commercially available products [2][10].
The FDA has also stated that, at this time, it does not intend to take action against a compounder for regularly compounding a copy if the compounder fills four or fewer prescriptions of that compounded product during a calendar month [2]. This is stated enforcement discretion, not a legal exemption. As of the FDA’s April 2026 statements, semaglutide and tirzepatide do not appear on the 503B bulks list or on the drug shortage list [2].
What is semaglutide sodium, and why does the FDA object to it?
Some compounders sell salt forms of semaglutide, such as semaglutide sodium and semaglutide acetate. These are different active ingredients from the ones in the approved drugs, which contain the base form of semaglutide [1][9]. The FDA states it does not have information on whether the salt forms have the same chemical and pharmacologic properties as the approved active ingredient, and that it is not aware of any lawful basis for their use in compounding [1]. The FDA has not concluded the salts are unsafe — it says it lacks the data and sees no lawful basis for compounding them.
Related peptides face a harder line. Retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition [1]. The FDA has warned telehealth companies, API distributors, and outsourcing facilities over retatrutide, and has also warned companies selling products labeled “for research purposes” or “not for human consumption” that were sold directly to consumers with dosing instructions [1].
How many adverse events has the FDA received?
As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 reports associated with compounded tirzepatide [1]. The agency notes it is not always possible to determine whether an adverse event directly resulted from the drug or whether other factors contributed [1].
These counts are likely an undercount. Federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to the FDA [1].
What dosing errors has the FDA reported?
The FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide [9]. In the reported cases, patients administered five to 20 times more than the intended dose when drawing from multiple-dose vials [9].
The FDA’s alert describes specific reported cases, not instructions: patients directed to administer 5 units (0.05 mL) on a U-100 insulin syringe mistakenly administered 50 units; and one provider who intended a 0.25 mg dose (5 units) prescribed 25 units instead, leading the patient to receive five times the intended dose and experience severe vomiting [9]. Reported overdose events included nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis, and gallstones [9].
The agency has also received adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed in doses beyond what is in the FDA-approved label — meaning more product in a single dose, more frequent dosing, or faster titration — some of them serious [1].
What quality problems has the FDA documented?
Beyond dosing, the FDA has documented several product-quality issues with compounded GLP-1s:
- Fraudulent labels. In some cases, the compounding pharmacies named on product labels do not exist; in others, the label names a real licensed pharmacy that, based on information the FDA gathered, did not compound the product [1].
- Shipping and storage. The FDA has received complaints that compounded injectable GLP-1s arrived warm or with inadequate ice packs, and recommends patients not use any injectable GLP-1 that arrives warm or with insufficient refrigeration [1].
- Multi-dose vials. The FDA recommends discarding a multi-dose vial within 28 days after first use, even if the compounder’s instructions say longer, and using a new, sterile needle and syringe for each dose [1].
- Imported ingredients. Under Import Alert 66-80, foreign GLP-1 active pharmaceutical ingredients not on the alert’s Green List can be detained without physical examination. The FDA evaluated 48 GLP-1 API sites and found 21% noncompliant under section 501 of the FD&C Act [8][1]. A revision of the import alert was published on August 21, 2026 [8].
What enforcement actions has the FDA taken?
The FDA has moved in waves against compounders and the companies that market their products:
| When | Action |
|---|---|
| September 2025 | More than 50 warning letters to GLP-1 compounders and manufacturers, most dated September 9, 2025, targeting “generic” and “same active ingredient” claims; recipients had 15 working days to respond [3] |
| February 6, 2026 | FDA announced intent to restrict GLP-1 APIs used in mass-marketed compounded drugs, naming Hims & Hers, with possible seizure and injunction [7] |
| March 3, 2026 | 30 warning letters to telehealth companies over sameness claims and branding that implied the telehealth firm was the compounder [4] |
| Week of June 15, 2026 | 25 more warning letters to telehealth companies, plus a new FDA telehealth compliance webpage [5][12] |
The FDA’s leadership changed along the way: Commissioner Marty Makary was dismissed in May 2026, Kyle Diamantas became acting commissioner, and CDER Acting Director Michael Davis publicly reaffirmed that compounded GLP-1 products are not FDA-approved and have not gone through the review required of approved drugs [5][13].
What did the FDA propose for the 503B bulks list in April 2026?
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances [6]. Comments were due by June 29, 2026, and the agency said it will consider submitted comments before making a final determination [6].
Commissioner Makary said at the time: “This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process while continuing to provide a transparent, science-based pathway for public input” [6].
Do states add their own rules on top of federal law?
States cannot fall below the federal compounding standard, but some add to it [10]. California’s rewritten compounding regulations, effective October 1, 2025, require pharmacists to verify and document a clinically significant, patient-specific difference, and require the certificate of analysis to name the active ingredient manufacturer [10]. Ohio’s July 2025 guidance treats semaglutide and tirzepatide as no longer compoundable as copies, prohibits retatrutide and cagrilintide, and its pharmacy board reports summarily suspending more than thirty clinics and med spas since the start of 2025 [10]. Washington issued a stop-service order on a GLP-1 sterile compounder [10]. Connecticut, Illinois, and South Carolina have pursued enforcement through attorney general consumer protection actions, while most states rest on the federal floor [10]. Lilly and Novo Nordisk have filed trademark, patent, and false advertising suits across dozens of jurisdictions [10].
What red flags should you watch for when buying online?
The FDA lists warning signs for telehealth companies: claims that the compounded drug is the same as an FDA-approved drug; deep discounts or prices that seem too good to be true; medicine that looks different from what you received before or arrives in damaged packaging or without instructions; no screening or prescription by a licensed doctor; no licensed doctor available to answer questions after delivery; spelling errors on the label; incorrect pharmacy addresses; and pharmacy names that may be fraudulent [1].
The FDA also targets specific marketing language: claims that a product comes from an “FDA-approved” or “FDA-licensed” pharmacy or facility (the FDA does not approve or license any facility), and claims that a compounded drug is “clinically proven” to produce the same result as an approved drug [12][5]. The FDA’s advice for patients is to obtain a prescription from their own doctor and fill it at a state-licensed pharmacy, and to use its BeSafeRx resources when buying medicines online [1].
Sources
- US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
- Wilson Sonsini. FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers. October 1, 2025.
- US Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s.
- Sheppard Mullin. FDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters. June 18, 2026.
- US Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List.
- US Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs.
- US Food and Drug Administration. Import Alert 66-80.
- US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products.
- Sheppard Mullin. Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides. August 6, 2026.
- McDermott Will & Emery. Court Backs FDA in Tirzepatide Compounding Case.
- US Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs.
- US Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. FDA, No. 25-10758. August 27, 2026.
- Clark Hill. Fifth Circuit Upholds FDA GLP-1 Shortage Decisions, Narrowing Path for Mass-Market Compounding. September 10, 2026.
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. The FDA states that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing, and that compounded products are not the same as the FDA-approved versions. The only FDA-approved semaglutide products are Wegovy injection, Ozempic injection, and Rybelsus tablets. Compounded drugs are also not generics, since generic drugs are FDA-approved.
Is compounded semaglutide illegal to buy or only to sell?
The FDA's enforcement actions target compounders, manufacturers, and marketers, not patients. The agency has sent warning letters to compounders and telehealth companies over false or misleading claims, and has said entities that fail to address violations may face seizure or injunction. Its advice to patients is to get a prescription from their own doctor and fill it at a state-licensed pharmacy.
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy compounds for an individual patient based on a prescription it receives, and may not regularly compound essentially copies of commercially available drugs. A 503B outsourcing facility compounds on a larger scale and generally cannot use bulk drug substances unless the substance is on the 503B bulks list or the drug is on the FDA shortage list.
What is semaglutide sodium, and why does the FDA object to it?
Semaglutide sodium and semaglutide acetate are salt forms that are different active ingredients from the base form used in the approved drugs. The FDA says it does not have information on whether the salts share the same chemical and pharmacologic properties as the approved ingredient, and it is not aware of any lawful basis for their use in compounding. The FDA has not concluded the salts are unsafe.
Can a pharmacy still compound semaglutide if a doctor adds vitamin B12?
Not usually. The FDA says it may consider semaglutide plus vitamin B12 (cyanocobalamin) essentially a copy of a commercially available drug when both are given by the same route and the amounts are within 10% of the commercial strengths. The exception is a prescriber-documented change producing a significant difference for an identified individual patient.
How many adverse events has the FDA received for compounded semaglutide?
As of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to the FDA, so the agency says these events are likely underreported. It is not always possible to determine whether the drug directly caused the event.
Did the courts side with the compounders or the FDA?
The FDA won at every stage. The Northern District of Texas denied the compounders' preliminary injunction on April 24, 2025 and entered summary judgment for the FDA on June 13, 2025. On August 27, 2026, the Fifth Circuit affirmed both the semaglutide and tirzepatide judgments in unpublished decisions, holding any notice-and-comment error was harmless and the delisting was not arbitrary or capricious.
What is the 503B bulks list, and what did the FDA propose in April 2026?
The 503B bulks list identifies bulk drug substances that outsourcing facilities may use in compounding. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list, finding no clinical need for outsourcing facilities to compound them from bulk substances. Comments were due June 29, 2026, and the agency will consider them before a final determination.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.